ReviewEuropean clinical respiratory journal2018
Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults.
Review in European clinical respiratory journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 54 citations in OpenAlex.
- Cumulative corticosteroid burden over 25 years in patients initiating biologic therapy for severe asthma: a nationwide cohort study.ERJ open research · 2026Article
- Tezepelumab in severe asthma: chest computed tomography assessment of airway remodeling and clinical remission.Frontiers in pharmacology · 2026Article
- Fixed airway obstruction and bronchodilator responsiveness phenotypes in severe asthma population from SANI registry.BMJ open respiratory research · 2025Article
- Burden of asthma by severity and exacerbation frequency among adult patients naive to biologic asthma therapy: A Finnish cohort study.The journal of allergy and clinical immunology. Global · 2025Article
- Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthma.The European respiratory journal · 2025Article
- European biologic training course for type 2 inflammation by EUFOREA in 2024: key facts and lessons learned.Frontiers in allergy · 2024Article
- Translation and cross-cultural adaptation of the self evaluation of breathing questionnaire (SEBQ) into Danish.European clinical respiratory journal · 2024Article
- Laboratory Test Results in Patients with Workplace Moisture Damage Associated Symptoms-The SAMDAW Study.Healthcare (Basel, Switzerland) · 2023Article
- Multidisciplinary approaches to identifying and managing global airways disease: Expert recommendations based on qualitative discussions.Frontiers in allergy · 2023Article
- Documentation of smoking in scheduled asthma contacts in primary health care: a 12-year follow-up study.NPJ primary care respiratory medicine · 2022Article
- Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma Register.ERJ open research · 2022Article
- Body mass index increase: a risk factor for forced expiratory volume in 1 s decline for overweight and obese adults with asthma.ERJ open research · 2022Article
- Age at asthma diagnosis is related to prevalence and characteristics of asthma symptoms.The World Allergy Organization journal · 2022Article
- Prevalence and predictors of occupational asthma among workers in detergent and cleaning products industry and its impact on quality of life in El Asher Men Ramadan, Egypt.Environmental science and pollution research international · 2022Article
- Participation in scheduled asthma follow-up contacts and adherence to treatment during 12-year follow-up in patients with adult-onset asthma.BMC pulmonary medicine · 2022Observational
- Determinants of Severe Asthma - A Long-Term Cohort Study in Northern Sweden.Journal of asthma and allergy · 2022Article
- Disease Control, Not Severity, Drives Job Absenteeism in Young Adults with Asthma - A Nationwide Cohort Study.Journal of asthma and allergy · 2022Article
- Eosinophilic airway diseases: basic science, clinical manifestations and future challenges.European clinical respiratory journal · 2022Review
- Patients' experiences of asthma exacerbation and management: a qualitative study of severe asthma.ERJ open research · 2021Article
- Saudi Arabian real-life experience with biologic therapy in severe asthma.Multidisciplinary respiratory medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 14 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although a minority of asthma patients suffer from severe asthma, they represent a major clinical challenge in terms of poor symptom control despite high-dose treatment, risk of exacerbations, and side effects. Novel biological treatments may benefit patients with severe asthma, but are expensive, and are only effective in appropriately targeted patients. In some patients, symptoms are driven by other factors than asthma, and all patients with suspected severe asthma ('difficult asthma') should undergo systematic assessment, in order to differentiate between true severe asthma, and 'difficult-to-treat' patients, in whom poor control is related to factors such as poor adherence or co-morbidities. The Nordic Consensus Statement on severe asthma was developed by the Nordic Severe Asthma Network, consisting of members from Norway, Sweden, Finland, Denmark, Iceland and Estonia, including representatives from the respective national respiratory scientific societies with the aim to provide an overview and recommendations regarding the diagnosis, systematic assessment and management of severe asthma. Furthermore, the Consensus Statement proposes recommendations for the organization of severe asthma management in primary, secondary, and tertiary care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.